Interpretation of the 2021 Asia-Pacific Vitreo-Retina Society Expert Consensus on the Treat-and-Extend Protocol for nAMD
10.3760/cma.j.cn115989-20240818-00234
- VernacularTitle:2021亚太玻璃体视网膜学会新生血管性AMD的治疗和延长方案专家共识解读
- Author:
Junran SUN
1
;
Xiaodong SUN
1
Author Information
1. 上海市第一人民医院眼科，上海 200080
- Publication Type:Journal Article
- Keywords:
Wet macular degeneration;
Angiogenesis inhibitors;
Treat-and-extend regimen;
Asia-Pacific Vitreo-Retina Society;
Interpretation of expert consensus
- From:
Chinese Journal of Experimental Ophthalmology
2025;43(1):9-17
- CountryChina
- Language:Chinese
-
Abstract:
The treat-and-extend (T&E) protocol for treating neovascular age-related macular degeneration (nAMD) is one of the commonly used anti-vascular endothelial growth factor (VEGF) treatment strategies in clinical practice.It effectively improves vision while extending treatment intervals and reducing the number of clinic visits.In the Asia-Pacific region, where medical resources are limited and patient compliance is often poor, the T&E protocol offers unique advantages.However, there are currently no guidelines on the T&E protocol in this region, and its clinical use lacks standardized treatment pathways.In 2021, the Asia-Pacific Vitreo-Retina Society (APVRS) expert panel reviewed and summarized clinical research on the anti-VEGF T&E protocol, combining this with clinical practice to develop a set of consensus recommendations for using the T&E protocol to treat nAMD in the Asia-Pacific region.This article reviews and interprets the latest T&E treatment protocol proposed by the APVRS expert panel to guide clinicians in standardized treatment.
